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Because it is clearly in the best interests of children with cystic fibrosis to be diagnosed early at b2 months, which can only be achieved
routinely by newborn screening, it can be argued that this should be a human right. However, if more harm than good is likely, or if regional
“readiness” does not exist, newborn screening should be deferred.
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plenary session at the 30th ECFS conference, the question was
posed: “Is newborn screening for CF a basic human right?”
When considered in the context of modern European and North
American health care, this is a most challenging topic and truly
is an “unanswered question.” Instructions from the confer-
ence organizers made it clear that “basic human right” means
entitlement — something an infant with cystic fibrosis (CF) is
entitled to have assured by regional health care delivery
systems.
The larger question, of course, relates to health care in
general. Is healthcare a basic human right? This has been
debated intensely since 1999 when the “Tavistock Group” [1]
asserted that “health care is a human right” and the first of five
major ethical principles that should govern health care systems.
Arguments against the assertion have raised issues such as the
difficulties inherent in defining health care and the implication
that if health care is a basic human right then providing it
becomes a “duty” [2]. While this debate will continue, it is
advantageous to focus on a limited component of the modern
health care system, namely newborn screening (NBS) and spe-
cifically for CF [3].☆ Presented at the 30th ECFS conference in Belek, Turkey on 16 June 2007.
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doi:10.1016/j.jcf.2008.01.001Depending on your perspective and your geographical sit-
uation, I believe the answer to the “basic human right” question
on NBS for CF is both “yes” and “no.” Interestingly, when the
audience of the ECFS plenary session was asked this question
and to raise their hands as to an affirmative or negative answer,
the majority voted “yes.” On the other hand, when the question
was posed again in a more focused, regionalized version about
the country of Japan where the incidence of CF is apparent-
ly ~1:350,000, very few answered “yes.” Obviously, therefore,
geographical circumstances, as well as other factors to be re-
viewed herein, might influence the answer to this question.
Furthermore, this “show of hands” exercise made it clear that
NBS is at the most a relative human right, but the important
question remains: “Is early diagnosis of CF a human right?”
1. New era in the care of children with cystic fibrosis
One of the factors influencing the answer to this question is
the context and capability of health care in the 21st century for
young children with CF. Clearly, we have reached a new era [2]
as summarized in Table 1. The most significant overarching
change is a paradigm shift in therapeutic strategy from primarily
intervention in individuals with illness (3 Is) to prevention in
presymptomatic populations (3Ps). This is not to imply that
intervention for illness does not occur in CF during the new
era because it does on a regular basis, but the predominant
philosophy is prevention or even preemption. Thus, efforts ared by Elsevier B.V. All rights reserved.
Table 1
The 21st century is a new era for children with CF
• An established trend of early diagnosis through NBS
• A paradigm shift in therapeutic strategy from intervention in individuals with
illnesses (3 Is) to prevention in presymptomatic populations (3Ps)⁎
• No longer dominated by intervention in individuals with illnesses
• But prevention in presymptomatic patients
Prevention of early deaths
Prevention of salt depletion
Prevention of malnutrition and growth failure
Prevention of “cross-infection”
Prevention of chronic PA and early mPA
Prevention of hospitalizations
Prevention (eventually) of lung disease
⁎The concept of transforming from the “3 Is” to the “3 Ps” was developed by the
author for lectures to medical students and practicing physicians while he was
serving as Dean of an institution transformed to the University of Wisconsin
School of Medicine and Public Health.
Table 2
The rationale for early diagnosis through newborn screening
A. The GI/nutrition rationale for NBS
1. CF patients are generally well nourished at birth
2. PI will develop in ~90% of patients by ~1 year
3. Severe malnutrition will develop in ~50% untreated
4. PI can be anticipated and malnutrition prevented
5. Long term benefits of normal nutrition are significant
B. The pulmonary rationale for NBS
1. The CF lung is normal at birth, but not for long.
2. Lung disease often develops as early as 2 months.
3. Pseudomonas aeruginosa (PA) colonization may occur in ~1/3 of undiagnosed
patients.
4. PA conversion to mucoid PA is of great long term risk for children with CF.
C. Other rationale
1. Psychological harm associated with the “diagnostic odyssey” [6] may be
prevented.
2. Parents are provided with informed reproductive options for future pregnancies.
3. Economic benefits may be realized for both diagnosis [22] and treatment [18].
4. Clinical research is facilitated [21], especially study of upstream preventive
strategies.
Table 3
Ethical principles providing more guidance for CF newborn screening
1. Respect for persons while assuring autonomy and allowing people to choose
for themselves.
2. Protect privacy in organizing and delivering information and care.
3. Beneficence with a favorable benefit–risk relationship (best interests principle)⁎
4. Non-malfeasance through efficient, effective program implementation/manage-
ment.
5. Justice for all persons with equitably delivered care.
⁎Best interests for people and populations.
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as 5% of CF patients [4,5]], salt depletion, malnutrition with
growth failure, “cross-infection” leading to acquisition of vir-
ulent respiratory pathogens, chronic Pseudomonas aeruginosa
(PA) infections and early development of mucoid PA. And,
eventually, with therapeutic strategies to correct the chloride
channel defect, even prevention of lung disease would become a
goal.
With these preventive opportunities already in hand, the con-
sequences of delayed diagnoses are quite disconcerting. Suffer-
ing of patients, parents, and siblings occurs unnecessarily with
diagnostic delays, and this often leads to parental anxiety, frus-
tration, and anger as they experience a diagnostic “odyssey” [6].
Added to the short-term risks of delayed diagnoses such as se-
vere malnutrition and chronic pulmonary infections, we now
know that long term implications may include failure to approach
genetic growth potential [7], impaired development of cognitive
function [8], and increased risk of early lung disease [9].
2. The rationale for newborn screening
Table 2 lists the gastrointestinal/nutritional and pulmonary
advantages of early diagnosis through newborn screening and
provides compelling rationale. In essence, except for patients
with the meconium ileus, infants with CF are generally healthy
at the time of birth. Their nutritional status is normal, and the
90% with classes I, II or III mutations who will develop pan-
creatic insufficiency (PI) can be anticipated and provided with
therapies to preempt malnutrition. Thus, they are quite likely to
grow in the normal range [7,10].
The pulmonary rationale for newborn screening is straight-
forward. Fortunately, the CF lung is normal at birth [11],
although this may not continue beyond 2 months of age [12,13].
To my knowledge, there has never been a CF patient diagnosed
promptly through newborn screening that showed PA in the
respiratory tract; in contrast, approximately one-third of patients
diagnosed after signs or symptoms already are colonized with
PA and many with mucoid PA [14].
In addition to the clinical rationale, there are other considera-
tions that may be compelling. Some of these are also listed inTable 2 and have implications for how CFNBS is performed, i.e.,
what test is used. Clearly, to provide reproductive counseling,
which many parents regard as a significant benefit, the IRT/DNA
strategy must be employed rather than IRT/IRT.
3. More rationale: ethical principles applied to CF newborn
screening
The question “to screen or not to screen” [15] ultimately
becomes an ethical argument when regions are well-prepared to
initiate NBS for CF, as discussed subsequently. The five ethical
principles generally applied to medical care and research are
listed in Table 3. The first two principles, respect for per-
sons and protecting privacy, are both important but have lim-
ited applicability to public health programs such as newborn
screening. Nevertheless, when screening programs are imple-
mented, respecting the autonomy of people and their privacy
must be given priority. The third principle, beneficence, is a
dominating consideration in the rationale for implementing CF
newborn screening. Beneficence requires clinicians taking care
of individual people and populations to achieve more good
than harm in their practices by consistently doing what is the
best interests of those served. Obviously, it is in no one's best
264 P.M. Farrell / Journal of Cystic Fibrosis 7 (2008) 262–265interest to be undiagnosed with a 5% mortality risk [4,5] or a
much higher probability of severe malnutrition [7].
Clearly, as an extension of beneficence, the principle of non-
malfeasance also applies because “not causing harm” relates to
having the infrastructure to implement and operate an efficient,
effective program. Obviously, early diagnosis through NBS
will not necessarily be beneficial without early detection and
treatment. A variety of observations [18,19] indicate that early
means by 2 months of age at the latest and ideally before then.
Thus, NBS-CF follow-up systems have a duty to implement and
manage efficiently and effectively.
Finally, the principle of justice is paramount in arguments to
implement NBS for CF. Indeed, screening is the only method of
diagnosis that may be considered equitable and egalitarian be-
cause every infant has the same excellent opportunity for early
diagnosis. Otherwise, the probability of early diagnosis depends
upon geographic, financial, and demographic factors. For in-
stance, those in rural areas are less likely to be well served than
those in urban communities, whereas access to health care in
some countries such as the USA depends largely on health
insurance and financial wherewithal. Furthermore, no matter
what the financial and geographic factors, girls with CF ex-
perience significantly longer delays in diagnosis than boys [16],
especially when they present with respiratory disease [17]; this
tragic situation which defies explanation thus far may be an
important factor in the reduced longevity of females with CF.
4. The “yes” and “no” answers to the human rights question
Because it is clearly the best interests and eminently fair for
every child with cystic fibrosis who has two CFTR mutations
that are classes I, II, or III to be diagnosed early, and since early
diagnosis [defined as b2 months of age [18,19]] to prevent
unnecessarily suffering can only be achieved routinely through
newborn screening, it may be argued that this is a human right if
the following four conditions apply:1) if you are born in a re-
gion with a significant incidence of CF (e.g., at least 1:10,000),
and 2) if a satisfactory newborn screening program for CF exists
or can be created, and 3) if follow-up of screen-positive families
is organized properly, and 4) if excellent CF leadership and
sustained funding are available. Research on newborn screening
for CF has demonstrated not only benefits but how programs
should be organized and managed [20]. It is fortunate that more
research has been done on CF newborn screening than for any
other genetic disease during the past two decades, as literature
searches reveal. In fact, comprehensive studies have enlightened
all aspects of diagnosis and treatment, although the delivery of
care and patient adherence have not been perfected anywhere.
On the other hand, the “no” response to the human rights
question applies if more harm than good is likely, or if regional
“readiness” does not exist [6], or if resources/services cannot
be sustained. As the CDC concluded [6], “the net balance of
benefits and risks is contingent on how newborn screening for
CF is implemented.” More information on benefits and risks
of NBS is provided in a recent article by Balfour–Lynn [21],
which concludes that “the task now is to ensure it is carried out
smoothly and effectively.”Acknowledgements
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